Medizinische Universit├Ąt Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Terbuch, A; Absenger, G.
Neoadjuvant treatment in non-small-cell lung cancer-the earlier, the better
MEMO-MAG EUR MED ONC. 2022; Doi: 10.1007/s12254-022-00828-3
Web of Science FullText FullText_MUG

 

Leading authors Med Uni Graz
Terbuch Angelika
Co-authors Med Uni Graz
Absenger Gudrun
Altmetrics:

Dimensions Citations:
Plum Analytics:


Scite (citation analytics):

Abstract:
Neoadjuvant checkpoint inhibition in resectable non-small-cell lung cancer (NSCLC) is safe and high major pathologic response (MPR) and pathologic complete response (pCR) rates can be achieved in combination with chemotherapy. The Checkmate 816 trial gives evidence that pathologic response also leads to EFS benefit. This opens new opportunities in the curative setting but also raises questions: What is the value of adjuvant treatment with checkpoint inhibitors? Or should we treat our patients peri-operatively? Which biomarkers can we use for treatment decisions and monitoring of curative patients? Targeted therapies in the neoadjuvant setting lead to promising response rates and data for EFS and overall survival are eagerly awaited.

Find related publications in this database (Keywords)
Neoadjuvant treatment
Pathologic complete response
Major pathologic response
Prognosis
Biomarker
© Med Uni GrazImprint